KLP Kapitalforvaltning AS Has $526,000 Stake in Merus N.V. $MRUS

KLP Kapitalforvaltning AS raised its stake in shares of Merus N.V. (NASDAQ:MRUS) by 9.9% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 10,000 shares of the biotechnology company’s stock after purchasing an additional 900 shares during the period. KLP Kapitalforvaltning AS’s holdings in Merus were worth $526,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in MRUS. GAMMA Investing LLC boosted its stake in shares of Merus by 2,153.6% in the 1st quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company’s stock worth $27,000 after buying an additional 603 shares during the last quarter. GF Fund Management CO. LTD. lifted its stake in Merus by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 1,753 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 315 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in Merus by 955.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,794 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 1,624 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Merus by 15.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,674 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 362 shares during the period. Finally, US Bancorp DE raised its holdings in Merus by 324.1% during the 1st quarter. US Bancorp DE now owns 2,935 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 2,243 shares during the period. Institutional investors and hedge funds own 96.14% of the company’s stock.

Merus Price Performance

MRUS stock opened at $94.89 on Friday. Merus N.V. has a 1 year low of $33.19 and a 1 year high of $95.04. The company has a market cap of $7.18 billion, a P/E ratio of -17.25 and a beta of 1.26. The firm has a 50-day moving average of $75.28 and a 200 day moving average of $59.55.

Merus (NASDAQ:MRUS) last announced its earnings results on Tuesday, August 5th. The biotechnology company reported ($2.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($1.06). Merus had a negative net margin of 685.64% and a negative return on equity of 50.28%. The business had revenue of $8.83 million for the quarter, compared to the consensus estimate of $9.77 million. On average, equities research analysts expect that Merus N.V. will post -3.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

MRUS has been the topic of several research analyst reports. Leerink Partners reaffirmed a “market perform” rating and issued a $97.00 price target (up previously from $95.00) on shares of Merus in a report on Monday, October 6th. Wall Street Zen lowered shares of Merus from a “hold” rating to a “sell” rating in a research report on Sunday, July 20th. Alliance Global Partners started coverage on shares of Merus in a research report on Monday, August 25th. They issued a “buy” rating and a $90.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Merus in a research report on Wednesday, October 8th. Finally, Truist Financial lowered shares of Merus from a “buy” rating to a “hold” rating and increased their target price for the stock from $88.00 to $97.00 in a report on Monday, September 29th. Four research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $93.12.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.